TABLE 1.
Patients' baseline characteristics
| Characteristic | Group and regimen (no. of patients)
|
|||||
|---|---|---|---|---|---|---|
| 1, ATV/SQV/RTV (49)
|
2, ATV/RTV+NRTI (72)
|
3, SQV/RTV+NRTI (90)
|
||||
| Mean or no. | % or range | Mean or no. | % or range | Mean or no. | % or range | |
| Male/female (no.) | 43/6 | 87.8/12.2 | 47/25 | 65.3/34.7 | 63/27 | 70.0/30.0 |
| Caucasian/other (no.) | 43/6 | 87.8/12.2 | 64/8 | 88.9/11.1 | 74/16 | 82.2/17.8 |
| Age (yr) | 45.1 | 28.0-71.0 | 41.5 | 23.0-72.0 | 41.0 | 19.0-60.0 |
| Body mass index (kg/m2) | 24.9 | 18.5-33.0 | 24.9 | 16.2-38.6 | 23.2 | 18.8-36.0 |
| CDC status C3/B3 (no.) | 39 | 79.6 | 46 | 63.9 | 55 | 61.1 |
| Hepatitis B virus s antigen (HBsAg)/HBeAg, HCV PCR positive (no.) | 6 | 12.2 | 18 | 25.0 | 11 | 15.3 |
| CD4 cell count/μl | 297 | 10-779 | 290 | 4-1,082 | 138 | 1-624 |
| HIV viral load, log10 | 3.02 | 1.28-5.88 | 3.71 | 1.28-6.00 | 4.72 | 1.28-6.00 |
| Previous treatments (no.) | 7.1 | 0-24 | 4.6 | 0-30 | 3.5 | 0-10 |
| Time to pharmacokinetic assessment (wks) | 5.3 | 2-24 | 16.0 | 2-140 | 8.0 | 2-48 |
| Treatment naive (no.) | 1 | 2.0 | 7 | 9.7 | 68 | 75.6 |
| Saquinavir formulation (no.) | ||||||
| SQV in soft-gelatin capsule | 10 | 20.4 | 43 | 47.8 | ||
| SQV in hard-gelatin capsule | 39 | 79.6 | 47 | 52.2 | ||
| NRTI comedication (no. receiving) | ||||||
| Abacavir | 7 | 9.7 | 16 | 17.8 | ||
| Didanosine | 25 | 34.7 | 9 | 10.0 | ||
| Emtricitabine | 19 | 26.4 | ||||
| Lamivudine | 24 | 33.3 | 81 | 90.0 | ||
| Stavudine | 3 | 4.2 | 4 | 4.4 | ||
| Tenofovir-DF | 53 | 73.6 | 20 | 22.2 | ||
| Zidovudine | 8 | 11.1 | 64 | 71.1 | ||